Key Points
- Director Adrian Krainer sold 33,243 shares of Stoke Therapeutics on March 10 at an average price of $39.74 for proceeds of about $1.32 million, reducing his stake by 10.5% to 283,302 shares (≈$11.26M).
- STOK traded down to $33.58 (down $2.90) with a market cap of ~$1.92 billion and a 1‑year range of $5.35 to $40.22, while its 50‑day and 200‑day moving averages are $32.66 and $29.46, respectively.
- Analysts hold a consensus rating of “Moderate Buy” with a $39.25 average price target (notably HC Wainwright raised its target to $50), and institutional activity includes Goldman Sachs boosting its stake to 1,662,039 shares.
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Arthur Tzianabos sold 4,355 shares of the firm's stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total value of $174,200.00. Following the transaction, the insider directly owned 31,339 shares of the company's stock, valued at approximately $1,253,560. This represents a 12.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Stoke Therapeutics Stock Down 6.9%
Shares of NASDAQ STOK traded down $2.53 during trading on Friday, reaching $33.95. The company had a trading volume of 739,715 shares, compared to its average volume of 729,700. The stock has a market cap of $1.94 billion, a P/E ratio of 51.02 and a beta of 1.07. The company's fifty day moving average price is $32.66 and its 200-day moving average price is $29.46. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $40.22.
Analysts Set New Price Targets
STOK has been the subject of several analyst reports. Wedbush raised their price target on shares of Stoke Therapeutics from $32.00 to $36.00 and gave the stock an "outperform" rating in a report on Monday, January 12th. Canaccord Genuity Group lifted their target price on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, January 5th. HC Wainwright boosted their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a "buy" rating in a report on Monday, December 15th. Chardan Capital upped their price target on shares of Stoke Therapeutics from $24.00 to $35.00 and gave the company a "buy" rating in a research report on Monday, January 5th. Finally, Wolfe Research assumed coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They issued an "outperform" rating and a $40.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $39.25.
Get Our Latest Report on Stoke Therapeutics
Institutional Investors Weigh In On Stoke Therapeutics
A number of large investors have recently bought and sold shares of STOK. Invesco Ltd. grew its stake in shares of Stoke Therapeutics by 24.7% in the 4th quarter. Invesco Ltd. now owns 259,543 shares of the company's stock valued at $8,238,000 after buying an additional 51,468 shares during the period. NewEdge Advisors LLC bought a new position in shares of Stoke Therapeutics in the fourth quarter valued at $330,000. Tudor Investment Corp ET AL bought a new position in shares of Stoke Therapeutics in the fourth quarter valued at $613,000. Readystate Asset Management LP purchased a new stake in Stoke Therapeutics in the 4th quarter valued at about $922,000. Finally, RTW Investments LP grew its holdings in shares of Stoke Therapeutics by 8.3% in the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company's stock valued at $176,057,000 after acquiring an additional 423,331 shares in the last quarter.
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.
The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
